🇺🇸 FDA
Pipeline program

Lubiprostone

URMC08-022LUB

Approved small_molecule completed

Quick answer

Lubiprostone for Multiple Sclerosis is a Approved program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda
Indication
Multiple Sclerosis
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials